European Heart Journal Advance Access originally published online on January 18, 2006
European Heart Journal 2006 27(7):802-807; doi:10.1093/eurheartj/ehi730
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prognostic significance of plasma osteopontin levels in patients with chronic stable angina
1Department of Cardiology, Alessandro Manzoni Hospital of Lecco, Lecco, Italy
2Interdepartmental Center for Research in Molecular Medicine (CIRMC), University of Pavia, Viale Taramelli 24, I-27100 Pavia, Italy
3Department of Cardiology, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
Received 20 September 2005; revised 16 December 2005; accepted 23 December 2005; online publish-ahead-of-print 18 January 2006.
* Corresponding author. Tel: +39 0382 528 341; fax: +39 0382 526 259. E-mail address: ccirmc{at}unipv.it
See page 766 for the editorial comment on this article (doi:10.1093/eurheartj/ehi743)
Aims Levels of the secreted glycophosphoprotein osteopontin (OPN) have been associated with the presence and extent of coronary artery disease (CAD). The present study assessed the relationship between plasma OPN concentrations and prognosis in patients with chronic stable angina (CSA).
Methods and results OPN was measured in baseline plasma samples from 799 patients with stable angina pectoris and angiographically documented CAD. Participants were prospectively followed-up for a median of 2.7 years (maximum 4.1 years). The primary study endpoint was the composite of non-fatal myocardial infarction and death from cardiovascular causes. In the univariate Cox proportional hazard analysis, the log-transformed OPN level [hazard ratio (HR) 1.79, 95% CI 1.35–2.36, P<0.001] was significantly related to adverse outcome. In addition, hypertension, levels of C-reactive protein, and statin use were associated with future adverse events. Levels of OPN (HR, 1.88; P<0.001) and C-reactive protein (HR, 1.42; P=0.003), as well as the presence of hypertension (HR, 2.39; P=0.008) remained statistically significant, independent predictors of adverse cardiovascular outcome in a multivariable Cox proportional hazard analysis.
Conclusion Baseline levels of OPN are an independent predictor of future adverse cardiac events in patients with CSA and may be useful for risk stratification.
Key Words: Osteopontin • Stable angina • Prognosis • Risk stratification
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Osteopontin, coronary calcification, and cardiovascular events: future diagnostic and therapeutic targets for disease prevention?
- Paul Schoenhagen
EHJ 2006 27: 766-767.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  S. H. Mangan, A. V. Campenhout, C. Rush, and J. Golledge Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-{alpha} associated with induction of angiopoietin-2 Cardiovasc Res, December 1, 2007; 76(3): 494 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gomez-Ambrosi, V. Catalan, B. Ramirez, A. Rodriguez, I. Colina, C. Silva, F. Rotellar, C. Mugueta, M. J. Gil, J. A. Cienfuegos, et al. Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3719 - 3727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakamachi, T. Nomiyama, F. Gizard, E. B. Heywood, K. L. Jones, Y. Zhao, L. Fuentes, K. Takebayashi, Y. Aso, B. Staels, et al. PPAR{alpha} Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes Diabetes, June 1, 2007; 56(6): 1662 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schoenhagen Osteopontin, coronary calcification, and cardiovascular events: future diagnostic and therapeutic targets for disease prevention? Eur. Heart J., April 1, 2006; 27(7): 766 - 767. [Full Text] [PDF]
|
|